West Pharmaceutical Services, Inc. · WST · FY2025 Q4 · Calendar Q1 2026

West Pharma maintains 2026 outlook as HVP demand outpaces supply

The supplied analysis provides evidence for a constructive one-year operating outlook: management cited HVP, biologics, biosimilars and Annex 1 demand, maintained FY2026 growth guidance, and is expanding capacity while reducing capex. The thesis is not risk-free because supply constraints, oral GLP-1 substitution and regulatory or tariff exposure could limit delivery.

Why did WST fall 1.0% after beating EPS estimates in FY2025 Q4?

Research this report with FN2. Free to start; review your question before sending.

Reported Before market openNYSEHealthcare $26.43B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $2.04 Consensus $1.83
EPS surprise +11.5% Reported versus consensus
Reported revenue $805.0M Consensus $794.9M
Revenue surprise +1.3% Reported versus consensus
Check the math in the surprise calculator >

Market reaction

prior-close to event-session close
Stock move -1.0% Event window
SPY move -1.5% Same window
Abnormal move +0.5% Stock minus SPY
Volume 1.7× Versus trailing sessions
Subsequent drift -3.3% Up to 20 sessions
WSTSPY benchmark

Ask FN2 about WST FY2025 Q4

Choose a question to continue your research

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Transcript intelligence

What changed

The current analysis shifts the focus from the prior quarter's guidance raise to maintained FY2026 guidance. It adds the planned mid-2026 SmartDose divestiture, lower 2026 capex, stronger free cash flow and evidence that HVP demand still exceeds supply.

Guidance delta

FY2026 guidance was maintained: 5%-7% organic revenue growth and approximately 10% EPS growth at the midpoint.

Key takeaways

  • Management described 2025 net sales above $3 billion and organic growth above 4%, led by high-value product components.
  • The FY2026 plan calls for 5%-7% organic revenue growth and approximately 10% EPS growth at the midpoint.
  • Capacity expansions in Dublin and Grand Rapids are intended to address demand that currently exceeds supply.
  • The SmartDose business sale is planned for mid-2026, with proceeds available for growth investment or shareholder returns.
  • The company is reducing 2026 capex to $250-$275 million while emphasizing free cash flow and margin improvement.

Management priorities

  • Expand HVP capacity and address supply constraints
  • Advance West Synchrony pre-fillable syringes and drug-handling operations
  • Complete the SmartDose divestiture
  • Develop elastomer formulations and pursue growth opportunities
  • Continue Annex 1 upgrade execution while reducing capex

Follow WST with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
WST REVENUE earnings history estimate and actual scatter chart 10 reported fiscal quarters and 4 future estimate-only quarters. Q4 '23 estimate $739M Q4 '23 actual $732M, miss Q1 '24 estimate $671M Q1 '24 actual $695M, beat Q2 '24 estimate $729M Q2 '24 actual $702M, miss Q3 '24 estimate $740M Q3 '24 actual $747M, beat Q2 '25 estimate $726M Q2 '25 actual $766M, beat Q3 '25 estimate $786M Q3 '25 actual $804M, beat Q4 '25 estimate $795M Q4 '25 actual $805M, beat Q1 '26 estimate $780M Q1 '26 actual $845M, beat Q2 '26 estimate $840M Q2 '26 actual $872M, beat Q3 '26 estimate $827M Q3 '26 actual $874M, beat Q4 '26 estimate $825M Q1 '27 estimate $859M Q2 '27 estimate $894M Q3 '27 estimate $930M
Show less

Analyst Consensus ?

ConsensusBuy16 ratings
Bullish1381.3%
Neutral212.5%
Bearish16.2%

Analyst 52W Price Targets

$390.3Current
$310Low
$384.86Average
$475High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
TD Cowen Buy BuyMaintainOct 30, 2026
Evercore ISI Group Outperform OutperformMaintainOct 30, 2026
Citigroup Buy BuyMaintainOct 30, 2026
Barclays Overweight OverweightMaintainOct 30, 2026
Morgan Stanley Overweight Equal WeightUpgradeSep 22, 2026
Show 11 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $390.3. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
JefferiesDavid Windley$475$412.62 +21.7%Nov 2, 2026
BarclaysLuke Sergott$440$372.64 +12.7%Oct 7, 2026
Morgan StanleyKallum Titchmarsh$400$361.73 +2.5%Sep 22, 2026
UBSAnalyst unavailable$415$338.06 +6.3%Sep 9, 2026
Evercore ISIAnalyst unavailable$425$333.12 +8.9%Jul 27, 2026
See 25 more

Track every rating change on WST the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies.…

Historical context

All WST earnings

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
ASND Ascendis Pharma A/S FY2026 Q3 · Calendar Q4 2026 +38.7% +3.0% Ascendis Q3 growth broadens the story, while execution risks remain
ALC Alcon Inc. FY2026 Q3 · Calendar Q4 2026 +2.2% -2.3% Alcon holds FY outlook as new launches meet IOL competition

Latest beats and misses

Who reports next

Get the WST recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-09-29T21:11:00.992723+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-29T21:11:00.990549+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-09-29. For educational purposes only; not investment advice.